Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SK Biopharmaceuticals Co. Ltd.

www.skbp.com/eng

Latest From SK Biopharmaceuticals Co. Ltd.

Major Milestone For SK Biopharm As Anti-Epileptic Gets US Approval

SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.

Approvals Neurology

Finance Watch: Two New Funds Provide $1.4bn For Health Care Ventures

Private Company Edition: GHO Capital will invest €975m in pharmaceutical and other opportunities in Europe, but Wellington’s $393m fund is focused on drug discovery and development. Also, Avidity raises $100m and Werewolf launches with $56m.

Financing StartUps and SMEs

Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
South Korea Financing

E2082 Discontinuation May Hit Eisai's Epilepsy Succession

Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.

Japan Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • SK Biopharmaceuticals Co. Ltd.
  • Senior Management
  • Jeong Woo Cho, PhD, Pres. & CEO
    Jiyoung Jung, VP, CFO
    Kiho Lee, PhD, VP, R&D
  • Contact Info
  • SK Biopharmaceuticals Co. Ltd.
    Pangyo,
    South Korea
UsernamePublicRestriction

Register